Etoposide is indicated for the treatment of small cell lung cancer (SCLC). It is commonly used in combination with other approved chemotherapeutic agents as a first-line treatment for patients diagnosed with this type of lung cancer.

Pharmacodynamics: Etoposide belongs to the podophyllotoxin derivative class and is a semisynthetic compound used in the treatment of certain cancers. It works by inhibiting mitosis through disruption of microtubule formation. Etoposide also blocks cell cycle progression at the premitotic phase (late S and G2 phases) without affecting nucleic acid synthesis.

Pharmacokinetics: After intravenous administration, etoposide exhibits biphasic elimination. It has an initial distribution half-life of approximately 1.5 hours and a terminal elimination half-life ranging from 4 to 11 hours. Total body clearance varies between 33–48 mL/min or 16–36 mL/min/m² and remains consistent across doses of 100–600 mg/m². Within this dose range, both the area under the plasma concentration-time curve (AUC) and peak plasma concentration (Cmax) increase proportionally with dose. Etoposide does not significantly accumulate in plasma when administered daily at 100 mg/m² for 4–5 days. The steady-state volume of distribution typically ranges from 18 to 29 liters or 7 to 17 L/m².

Small cell lung cancer: The dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m²/day for 4 days to 50 mg/m²/day for 5 days. Or, as directed by the registered physicians.

In patients with impaired renal function: The initial dose modification should be considered based on measured creatinine clearance: >50 mL/min: 100% of dose; 15–50 mL/min: 75% of dose. Subsequent Etoposide dosing should be based on patient tolerance and clinical effect. Data are not available in patients with creatinine clearances <15 mL/min and further dose reduction should be considered in these patients.

When Etoposide is administered together with high-dose cyclosporine A resulting in blood concentrations above 2000 ng/mL, it can significantly increase the exposure of etoposide. In such cases, Etoposide exposure may increase by about 80%, while the total body clearance of the drug decreases by approximately 38% compared with the use of Etoposide alone.

Laboratory Monitoring: During treatment with Etoposide, regular complete blood count (CBC) tests should be performed. These tests should be conducted before each treatment cycle and at appropriate intervals during and after therapy. At least one blood count assessment should be done before each dose of Etoposide.

Etoposide should not be used in patients who have previously experienced hypersensitivity or allergic reactions to Etoposide or any of its components.

Hematologic Toxicity: The most significant side effect of Etoposide is bone marrow suppression (myelosuppression), which is dose-dependent. The lowest levels of granulocytes usually occur 7–14 days after treatment, and the lowest platelet levels occur 9–16 days after treatment. Bone marrow usually recovers by about day 20. Fever and infections may occur in patients with neutropenia. Rarely, acute leukemia has been reported in patients receiving Etoposide with other anticancer drugs.

Gastrointestinal Toxicity: Nausea and vomiting are the most common gastrointestinal side effects. These symptoms are usually mild to moderate and can often be managed with antiemetic medications. Mucositis and esophagitis may also occur. Gastrointestinal side effects may occur slightly more often with oral administration than with intravenous infusion.

Hypotension: Temporary low blood pressure has been reported in about 1–2% of patients after rapid intravenous administration. This effect is generally not associated with heart toxicity and can be prevented by administering Etoposide slowly over 30–60 minutes.

Allergic Reactions: Rare anaphylactic-like reactions may occur, characterized by symptoms such as fever, chills, rapid heartbeat, breathing difficulty, bronchospasm, and low blood pressure. These reactions usually resolve after stopping the infusion and administering supportive medications such as antihistamines, corticosteroids, or fluids. However, in rare cases, severe reactions may occur.

Alopecia: Hair loss is common and may occur in up to 66% of patients, but it is usually reversible after treatment.

Other Reactions: Other less common side effects include abdominal pain, fatigue, weakness, constipation, swallowing difficulty, somnolence, temporary vision disturbances, lung inflammation, seizures, skin reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, pigmentation changes, and radiation recall dermatitis.

Pregnancy Category D. There are no adequate and well-controlled studies of Etoposide in pregnant women. Etoposide has been reported to pass into human breast milk, and therefore breastfeeding should be avoided during treatment.

Patients receiving Etoposide must be carefully monitored for bone marrow suppression, both during and after treatment. Blood tests including platelet count, hemoglobin, and white blood cell count should be performed before treatment and before each cycle. If platelet counts fall below 50,000/mm³ or neutrophil counts fall below 500/mm³, treatment should be delayed until recovery. Physicians should also be aware of the possibility of severe allergic reactions, which may include chills, fever, bronchospasm, shortness of breath, and hypotension. To minimize the risk of hypotension, Etoposide should always be administered slowly by intravenous infusion over 30–60 minutes. Before prescribing Etoposide, the physician should carefully balance the benefits of treatment against the potential risks of side effects. If severe toxicity occurs, the dose may need to be reduced or treatment discontinued. Patients with low serum albumin levels may have a higher risk of Etoposide toxicity.

Cytotoxic Chemotherapy

Etoposide capsules should be stored in a refrigerator at 2°C–8°C. Under these conditions, the capsules remain stable for up to 24 months.